Skip to main content
. Author manuscript; available in PMC: 2022 Sep 5.
Published in final edited form as: J Immunol. 2012 Feb 15;188(7):3315–3322. doi: 10.4049/jimmunol.1102775

Table III.

Candidate SNP (rs9916629) and secondary outcome of NK cell functional response following stimulation

Condition Variable Median Percentage of Expression (Quartile 1–Quartile 3)
Unadjusted
Multivariatea
CC (n = 8) CT (n = 43) TT (n = 45) Direction
of Effect
p Direction
of Effect
p
721.221 CD107a/NK 11.18 (9.02–14.9) 9.72 (7–14.9) 8.04 (5.7–10.4) 0.021 0.017
721.221 IFN-γ/NK 3.76 (2.6–7.7) 3.2 (1.62–5.07) 3.38 (2.19–4.89) 0.76 0.82
721.221 MIP-1β/NK 30.8 (28.7–41.8) 31.1 (22.5–42.3) 37.15 (31.25–41.95) 0.062 0.11
721.221 CD107a/CD56bright 10.12 (8.3–15.7) 9.83 (5.64–14.3) 6.5 (4.45–10.6) 0.02 0.023
721.221 IFN-γ/CD56bright 1.44 (0.87–3.14) 1.32 (0.71–2.66) 1.5 (1–2.62) 0.89 0.84
721.221 MIP-1β/CD56bright 15.7 (9.26–27.7) 15.7 (12.25–22.55) 15.6 (11.2–25.25) 0.63 0.77
721.221 CD107a/CD56dim 12.2 (7.95–14.6) 9.72 (6.97–14.5) 7.68 (5.47–9.92) 0.021 0.018
721.221 IFN-γ/CD56dim 4.8 (2.98–8.82) 3.39 (1.88–5.39) 3.59 (2.29–5.44) 0.58 0.63
721.221 MIP-1β/CD56dim 38.8 (32.4–47.2) 38.2 (28.6–46.9) 41.6 (34.1–48.35) 0.18 0.24
K562 CD107a/NK 25.55 (23.15–34.65) 26.2 (20.9–33.9) 25.1 (16.6–30.7) 0.092 0.06
K562 IFN-γ/NK 5.31 (2.42–8.3) 3.83 (2.84–6.02) 4.34 (2.65–7.02) 0.77 0.72
K562 MIP-1β/NK 44.4 (40.5–48.9) 43.1 (35.1–51.3) 47.3 (39.85–56.25) 0.039 0.10
K562 CD107a/CD56bright 22.65 (15.35–28.15) 20 (12–27.7) 16.8 (13.3–23.6) 0.18 0.17
K562 IFN-γ/CD56bright 1.21 (0.75–2.68) 1.53 (0.84–2.04) 1.49 (0.89–2.11) 0.92 0.92
K562 MIP-1β/CD56bright 16.6 (8.44–23.5) 18.5 (14.5–22.3) 18.75 (11.85–23.9) 0.48 0.69
K562 CD107a/CD56dim 26.7 (25.15–40.7) 27.7 (21.6–35) 26 (17.5–31) 0.081 0.056
K562 IFN-γ/CD56dim 6.1 (3.27–10.11) 4.48 (3.35–6.49) 5.03 (2.86–7.57) 0.45 0.41
K562 MIP-1β/CD56dim 51.7 (45.7–59.9) 53 (41.9–57.2) 52.3 (42.35–62.6) 0.31 0.53
815AB CD107a/NK 37.1 (25.5–42.65) 36.5 (30.4–42.9) 33.1 (24.9–42.1) 0.64 0.48
815AB IFN-γ/NK 7.09 (5.65–10.54) 5.5 (3.61–7.88) 7.73 (4.21–10.84) 0.44 0.57
815AB MIP-1β/NK 67.6 (59.1–78.6) 72.4 (60–79.9) 80.8 (72.95–85.4) 0.016 0.039
815AB CD107a/CD56bright 18.6 (10.16–27.65) 18.3 (11.7–25.7) 15 (9.27–20.6) 0.5 0.48
815AB IFN-γ/CD56bright 1.37 (1.24–2.62) 1.34 (0.66–2.11) 1.61 (0.86–2.15) 0.82 0.84
815AB MIP-1β/CD56bright 26.2 (10.7–29.2) 19.5 (13.4–26.1) 20.55 (14.8–28) 0.49 0.67
815AB CD107a/CD56dim 42.55 (30.25–46.4) 38.6 (32.4–45.1) 33.7 (25.8–44.1) 0.44 0.34
815AB IFN-γ/CD56dim 9.8 (6.61–14.4) 7.22 (5.41–10.1) 9.41 (5.19–12.3) 0.89 0.82
815AB MIP-1β/CD56dim 77.4 (72–90.7) 84.7 (76.5–87.8) 86.75 (79.85–90.15) 0.19 0.3
PMA CD107a/NK 33.45 (13.7–48.35) 13.9 (8.39–28.3) 10.3 (5.88–15.3) 0.0014 0.0011
PMA IFN-γ/NK 23.45 (15.8–38.9) 9.95 (5.11–18.1) 9.59 (3.41–18.7) 0.031 0.054
PMA MIP-1β/NK 75.1 (64.3–81.7) 55.6 (47–65.2) 58.85 (34.65–73.9) 0.38 0.44
PMA CD107a/CD56bright 59.35 (30.35–75.95) 36.5 (20.9–61.3) 24.5 (15.4–42.3) 0.0055 0.007
PMA IFN-γ/CD56bright 26.15 (21.35–52.35) 20.2 (9.15–29.5) 16.3 (10.8–26.4) 0.04 0.056
PMA MIP-1β/CD56bright 82.9 (80.6–93.6) 72.7 (63–81.8) 74.05 (60.5–85) 0.46 0.4
PMA CD107a/CD56dim 19.6 (8.46–35.4) 9.85 (4.63–16.7) 5.72 (3.78–10.7) 0.0096 0.0098
PMA IFN-γ/CD56dim 23.9 (11.65–30.7) 7.99 (2.8–15.4) 7.81 (2.42–18.4) 0.1 0.17
PMA MIP-1β/CD56dim 69.4 (60.5–80.3) 61.5 (43.3–72.5) 62.55 (29.25–77.05) 0.27 0.34

Genotype and quantitative trait association were analyzed using PLINK with the C allele of rs9916629 as the reference allele. Direction of effect is relative to the C allele and is determined from the beta value. In the multivariate analysis, association between rs9916629 and the phenotype was further adjusted for age and sex as covariates. Boldface indicates a p value meeting a Bonferroni-corrected threshold for multiple comparisons. 721.221, HLA class I-deficient B cell line; 815AB, p815 Ab (a mouse leukemic cell line coated with specific Ab; Ab-dependent cell-mediated cytotoxicity); CD107a, marker of degranulation; IFN-γ, IFN-γ–secreting NK cells; K562, MHC-devoid target cell line; MIP-1β, macrophage inflammatory protein-1β–secreting NK; PMA, phorbol 12-myristate 13-acetate and ionomycin (positive control).

a

Outcomes were adjusted for the appropriate background (media alone or uncoated p815 cell line).